2023 ASH Annual Meeting & Exposition

Gloria  Espinosa, PharmD, MAT, BCOP, of Thomas Jefferson University Hospital, comments on the safety data of the FLT3 inhibitor quizartinib in patients with FLT3-ITD–positive acute myeloid leukemia...

Gloria Espinosa, PharmD, MAT, BCOP, of Thomas Jefferson University Hospital, discusses efficacy and safety data for the first-in-class menin inhibitor, revumenib, in patients with relapsed/refractory KMT2A-rearranged acute leukemia...

Tiffany Richards, PhD, ANP-BC, AOCNP®, of The University of Texas MD Anderson Cancer Center, reviews updated efficacy and safety data for BMS-986393 (CC‑95266), a GPRC5D-targeted autologous chimeric antigen receptor (CAR) T-cell therapy in patients with relapsed/refractory multiple myeloma...

Tiffany Richards, PhD, ANP-BC, AOCNP®, of The University of Texas MD Anderson Cancer Center, examines daratumumab (DARA) plus bortezomib, lenalidomide, and dexamethasone (VRd) vs...

Gloria Espinosa, PharmD, MAT, BCOP, of Thomas Jefferson University Hospital, discusses the delayed administration of pegaspargase for adults with acute lymphoblastic leukemia, which led to a lower rate of high-grade hepatotoxicity and subsequent treatment dose modifications while maintaining a similar response rate (Abstract 4239)...

Tiffany Richards, PhD, ANP-BC, AOCNP®, of The University of Texas MD Anderson Cancer Center, dives into an analysis of minimal residual disease (MRD) negativity from a phase 1/2 trial in t(11;14)-positive relapsed/refractory multiple myeloma...

Amber Koehler, MPAS, PA-C, of Mayo Clinic discusses an updated analysis of the CD20xCD3 T-cell engaging bispecific antibody, mosunetuzumab, in patients with relapsed/refractory follicular lymphoma and 2 or more prior lines of therapy...

Amber Koehler, MPAS, PA-C, of Mayo Clinic, summarizes key points from an abstract she presented at the ASH Annual Meeting...

Amber Koehler, MPAS, PA-C, of Mayo Clinic, reports on the favorable outcomes and better tolerability of nivolumab (N) with doxorubicin, vinblastine, and dacarbazine (AVD) compared with brentuximab vedotin (BV) with AVD in patients with newly diagnosed advanced stage Hodgkin Lymphoma (Abstract 181)...